Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Zevra Therapeutics in a report issued on Thursday, August 6th. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2026 earnings at $0.13 EPS. Get Zevra Therapeutics alerts:Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its earnings results on Wednesday, August 5th. Zevra Therapeutics Company Profile(Get Free Report)Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. Recommended StoriesReceive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.